Recent Updates
Recently added Catalysts
GRML Positive Sentiment Score: 85/100

Klotho Neurosciences Raises Over $11 Million, Retires All Debt, and Exceeds NASDAQ STOCKHOLDERS' Equity Requirement Highlights: Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants.

Key Takeaway: Klotho Neurosciences, Inc. has raised over $11 million through the exercise of existing warrants, enhancing its financial standing. The company has retired all its outstanding debt, achieving a debt-free balance sheet. Furthermore, Klotho Neurosciences believes it now surpasses the NASDAQ stockholders' equity requirements, demonstrating improved compliance with market regulations. This financial boost aims to support its innovative research in gene and cell therapies for neurodegenerative diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successfully raised over $11 million in funding.
  • Retired all outstanding debt, resulting in a debt-free balance sheet.
  • Exceeds NASDAQ stockholders' equity requirement.

Full Press Release Details

Neurosciences Raises Over $11 Million, Retires All Debt,
and Exceeds NASDAQ STOCKHOLDERS' Equity Requirement
June 16, 2025 -Cision Newswire - New York, NY. Klotho Neurosciences,
Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised
over $11 million in funding through the exercise of existing warrants by investors. The Company believes that it now surpasses Nasdaq's
stockholders' equity requirement requirements outlined in its Nasdaq compliance plan.
In addition, the Company utilized $3.1 million of the funds raised
to extinguish all outstanding debt, resulting in a debt-free balance sheet.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and
gene therapies using an important human protein derived from the Company's patented form of the "anti-aging" human Klotho
gene (s-KL) and its novel promoter and delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders
such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs
using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who
are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Investor Contact and Corporate Communications
- Jeffrey LeBlanc, CFO
Forward-Looking Statements:
This press release contains forward-looking statements.
These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements generally are identified by the words "believe," "project," "expect,"
"anticipate," "estimate," "intend," "strategy," "future," "opportunity,"
"plan," "may," "should," "will," "would," "will be," "will
continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking
statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements
are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as
a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking
statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional
opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company
operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed
or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could
cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents
are available on the SEC's website, www.sec.gov. All information provided herein is as of the date of this press release, and the
Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Frequently Asked Questions

How much funding did Klotho Neurosciences raise?

Klotho Neurosciences raised over $11 million through warrant exercises.

What requirement did Klotho Neurosciences exceed?

The company exceeded Nasdaq's stockholders' equity requirement.

What did the company do with $3.1 million of the funds?

They used it to eliminate all outstanding debt, achieving a debt-free status.

What disorders does Klotho target with its therapies?

The company targets neurodegenerative and age-related disorders like ALS and Alzheimer's.

Who manages Klotho Neurosciences?

It is managed by a team experienced in biopharmaceutical development and commercialization.

Last updated: Jun 16, 2025